294 related articles for article (PubMed ID: 18083549)
21. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
[TBL] [Abstract][Full Text] [Related]
22. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
23. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.
Yao Q; Zhang R; Guo L; Li M; Chen C
J Immunol; 2004 Aug; 173(3):1951-8. PubMed ID: 15265929
[TBL] [Abstract][Full Text] [Related]
24. Virus-like particles: designing an effective AIDS vaccine.
Young KR; McBurney SP; Karkhanis LU; Ross TM
Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718
[TBL] [Abstract][Full Text] [Related]
25. Meeting report VLPNPV: Session 3: Immune responses.
Morrison TG
Hum Vaccin Immunother; 2014; 10(10):3064-7. PubMed ID: 25529229
[TBL] [Abstract][Full Text] [Related]
26. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
27. [Virus-Like Particles as an Instrument of Vaccine Production].
Syomin BV; Ilyin YV
Mol Biol (Mosk); 2019; 53(3):367-379. PubMed ID: 31184601
[TBL] [Abstract][Full Text] [Related]
28. Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.
Tornesello AL; Tagliamonte M; Buonaguro FM; Tornesello ML; Buonaguro L
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214685
[TBL] [Abstract][Full Text] [Related]
29. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
[TBL] [Abstract][Full Text] [Related]
30. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
31. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
[TBL] [Abstract][Full Text] [Related]
32. Efficient self-assembly and protective efficacy of infectious bursal disease virus-like particles by a recombinant baculovirus co-expressing precursor polyprotein and VP4.
Lee HJ; Kim JY; Kye SJ; Seul HJ; Jung SC; Choi KS
Virol J; 2015 Oct; 12():177. PubMed ID: 26502988
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
Villa LL
Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
[TBL] [Abstract][Full Text] [Related]
34. Construction and Immunogenicity of Novel Chimeric Virus-Like Particles Bearing Antigens of Infectious Bronchitis Virus and Newcastle Disease Virus.
Wu X; Zhai X; Lai Y; Zuo L; Zhang Y; Mei X; Xiang R; Kang Z; Zhou L; Wang H
Viruses; 2019 Mar; 11(3):. PubMed ID: 30871190
[TBL] [Abstract][Full Text] [Related]
35. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
[TBL] [Abstract][Full Text] [Related]
37. Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Schiller JT; Lowy DR
Expert Opin Biol Ther; 2001 Jul; 1(4):571-81. PubMed ID: 11727495
[TBL] [Abstract][Full Text] [Related]
38. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
Hankaniemi MM; Stone VM; Andrejeff T; Heinimäki S; Sioofy-Khojine AB; Marjomäki V; Hyöty H; Blazevic V; Flodström-Tullberg M; Hytönen VP; Laitinen OH
Antiviral Res; 2019 Nov; 171():104595. PubMed ID: 31491431
[TBL] [Abstract][Full Text] [Related]
39. Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot-and-mouth disease virus as a bivalent vaccine candidate.
Lei Y; Shao J; Zhao F; Li Y; Lei C; Ma F; Chang H; Zhang Y
J Med Virol; 2019 Dec; 91(12):2142-2152. PubMed ID: 31347713
[TBL] [Abstract][Full Text] [Related]
40. Virus-like particles: potential veterinary vaccine immunogens.
Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
